abbvie-gp2017
Phase 2
AbbVieabbvie-gp2017 is one of 15 therapeutic programs targeting Lupus. It is currently in Phase 2.
1
Indications
0
Total Trials
0
Active Trials
14
Competitors
Pipeline
Status by Indication[1]
Competition
Competitive Landscape
16 competitors in Lupus
#DrugCompanyPhaseTrials
1Olumiant
Eli LillyApproved
Sotyktu
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Saphnelo
AstraZenecaPhase 3
Farxiga
AstraZenecaPhase 3
Xarelto
WWim Janssens
Phase 3
Vyvgart
ArgenxPhase 3
LUNSUMIO
RochePhase 2
MEDI3506
AstraZenecaPhase 3
TAK-079
TakedaPhase 2
Otilimab
GSKPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for abbvie-gp2017. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2
- Company